Methoclocinnamox: Time course of changes in alfentanil-reinforced responding in rhesus monkeys

Psychopharmacology

Volumn 148, Issue 4, 2000, Pages 393-399

  Briscoe, R J ^a,d   Winger, G ^a   Lewis, J W ^c   Woods, J H ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d MPI RESEARCH   (United States)

Author keywords

Alfentanil; Buprenorphine; Methoclocinnamox; Operant responding; Opioid receptor; Self administration; Time course

Indexed keywords

ALFENTANIL; BUPRENORPHINE; CLOCINNAMOX; LONG ACTING DRUG; METHOCLOCINNAMOX; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; PARTIAL AGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENCY; DRUG SELF ADMINISTRATION; FEMALE; INSTRUMENTAL CONDITIONING; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; REINFORCEMENT; RHESUS MONKEY;

EID: 0034121458     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130050068     Document Type: Article

References (21)

1. Aceto MD, Bowman ER, May EL, Harris LS, Woods JH, Smith CB, Medzihradsky F, Jacobson AE (1989) Very long-acting narcotic antagonists: the 14-beta-p-substituted cinnamoylaminomorphinones and their partial mu agonist codeinone relatives. Arzneimittelforschung 39:570-575
2. Amass L, Bickel WK, Crean JP, Blake J, Higgins ST (1998) Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology 136: 217-225
3. Bickel WK, Amass L (1995) Buprenorphine treatment of opioid dependence: a review. Exp Clin Psychopharmacol 3:477-489
4. Butelman ER, Lewis JW, Woods JH (1996) Methoclocinnamox: agonist and antagonist effects of a novel long-lasting opioid in rhesus monkeys. J Pharmacol Exp Ther 279:934-938
5. Cowan A, Lewis JW, Macfarlane IR (1977) Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol 60:537-545
6. Deneau GA, Yanagita T, Seevers MH (1969) Self-administration of psychoactive substances by the monkey-a measure of psychological dependence. Psychopharmacologia 16:30-48
7. Hambrook J, Ranee M (1976) The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz H (ed) Opiates and endogenous peptides. North-Holland, Amsterdam, pp 295-301
8. Husbands SM, Sadd J, Broadbear JH, Woods JH, Martin J, Traynor JR, Aceto MD, Bowman ER, Harris LS, Lewis JW (1998) 3-Alkyl ethers of clocinnamox: delayed long-term μ-antagonists with variable μ efficacy. J Med Chem 41:3493-3498
9. Kosten TR, Rosen MI, Schottenfeld R, Ziedonis D (1992) Buprenorphine for cocaine and opiate dependence. Psychopharmacol Bull 28:15-19
10. Lewis JW (1985) Buprenorphine. Drug Alcohol Depend 14:363-372
11. Lukas SE, Griffiths RR, Brady JV (1983) Buprenorphine self-administration by the baboon: comparison with other opioids. NIDA Res Monogr 43:178-183
12. Mello NK, Bree MP, Mendelson JH (1981) Buprenorphine self-administration by rhesus monkey. Pharmacol Biochem Behav 15:215-225
13. Walker EA, Butelman ER, DeCosta BR, Woods JH (1993) Opioid thermal antinociception in rhesus monkeys: receptor mechanisms and temperature dependency. J Pharmacol Exp Ther 267:280-286
14. Walker EA, Zernig G, Woods JH (1995) Buprenorphine antagonism of mu opioids in the rhesus monkeys tail-withdrawal procedure. J Pharmacol Exp Ther 273:1345-1352
15. Winger G, Woods JH (1996) Effects of buprenorphine on behavior maintained by heroin and alfentanil in rhesus monkeys. Behav Pharmacol 7:155-159
16. Winger G, Palmer RK, Woods JH (1989) Drug-reinforced responding: rapid determination of dose-response functions. Drug Alcohol Depend 24:135-142
17. Winger G, Skjoldager P, Woods JH (1992) Effects of buprenorphine and other opioid agonists and antagonists on alfentanil-and cocaine-reinforced responding in rhesus monkeys. J Pharmacol Exp Ther 261:311-317
18. Winger G, Woods JH, Hursh SR (1996) Behavior maintained by alfentanil or nalbuphine in rhesus monkeys: fixed-ratio and time-out changes to establish demand curves and relative reinforcing effectiveness. Exp Clin Psychopharmacol 4:131-140
19. Woods JH, Lewis JW, Winger G, Butelman E, Broadbear J, Zernig G (1995) Methoclocinnamox: a μ partial agonist with pharmacotherapeutic potential for heroin abuse. NIDA Res Monogr 147:195-219
20. Zernig G, Broadbear JH, Lewis JW, Woods JH (1995) Opioid agonist effects on mouse writhing after irreversible mu receptor blockade with clocinnamox. Exp Clin Psychopharmacol 3: 323-329
21. Zernig G, Lewis JW, Woods JH (1997) Clocinnamox inhibits the intravenous self-administration of opioid agonists in rhesus monkeys: a comparison with effects on opioid agonist-mediated antinociception. Psychopharmacology 129:233-242